Healthcare stocks are under pressure as patents expire and margins are pressed. Consider selling these 6 laggards from the portfolio. More
AZN
Recent Articles
Forecast: Top 15 Pharma Companies in 2018
Novartis will be No. 1, and just one U.S. firm will remain among the top 5, according to EvalutePharma's research. More
AstraZeneca CEO Resigns, Shares Drop
CEO David Brennan departs after the company reported lower earnings and sales for the last quarter and a diminished outlook for the year. More
AstraZeneca Inks $1.26B Deal With Ardea
U.K.-based pharma AstraZeneca announced it's purchasing U.S. biotech company Ardea Biosciences for $1.26 billion. More
Cue the Biotech M&A Attack!
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road. More
Stock Pick of The Day: Dyax
Dyax is a maker of anti-inflammation drugs, an area with a growing base of patients. While in the early stages of growth, the company shows great promise. More
Here Comes a Bidding War for Amylin
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share. More
